1. Introduction {#sec1}
===============

Adolescent idiopathic scoliosis (AIS), accounting for 90% of all idiopathic scoliosis (IS) cases, affects more than 2% of the pediatric population and results in more than 600,000 physician visits annually \[[@B1]\]. Approximately, 1.5% patients ultimately need surgical correction for their curvature \[[@B2]\]. However, the causes involved in AIS remain obscure.

Genetic twin studies and observation of familial aggregation have revealed significant genetic contribution to IS \[[@B3], [@B4]\]. A genetic survey study reported that an overall risk of IS in first-degree relatives was up to 11%, as compared to 2.4 and 1.4% in second- and third-degree relatives, respectively. These studies indicate that IS is an inheritable complex disease. Molecular studies found that some critical regions on chromosomes were potentially important for the occurrence of scoliosis \[[@B5], [@B6]\]. Genome-wide association studies of AIS in case-control cohorts also located candidate susceptibility genes, and these findings indicate that single nucleotide polymorphisms are valuable for the AIS prognosis \[[@B7]\]. However, inconsistent outcomes were observed among studies concerning the candidate genes in AIS \[[@B8]--[@B11]\]. Totally, the inheritance mode and pathogenic gene of AIS is uncertain until today.

Recent technological advances reveal that a major portion of the genome is being transcribed and that protein-coding sequences only account for a minority of cellular transcriptional output. MicroRNAs are endogenously expressed noncoding transcripts, shorter than 20 nucleotides. MicroRNA silences gene expression by targeting specific mRNAs on the basis of sequence recognition \[[@B12]\]. Long noncoding RNAs (lncRNAs) are transcripts longer than 100 nucleotides. lncRNAs in most cases mirror the features of protein-coding genes except that the former does not contain a functional open reading frame. A handful of studies have implicated that lncRNAs are involved in a variety of disease states \[[@B13]\] and altered lncRNA levels can result in aberrant expression of gene products that may contribute to many biological processes and human diseases \[[@B14]--[@B16]\]. Circulating levels of lncRNAs were reported to reflect local pathophysiological conditions \[[@B17], [@B18]\]. Expression level of RNA in peripheral blood has been used to evaluate local circumstance of spine \[[@B19], [@B20]\]. However, the expression of lncRNAs and their functions in AIS are still unknown.

In the present study, we measured lncRNAs expression in AIS patients using microarray and quantitative PCR (qPCR) analysis. Our results disclosed lncRNAs expression profiles and provide new information for further exploration of pathogenesis and prognosis of AIS.

2. Materials and Methods {#sec2}
========================

2.1. Patients {#sec2.1}
-------------

Written informed consent was obtained from all participants. The study was approved by the Institutional Review Board of Chinese Academy of Medical Sciences and Peking Union Medical College Hospital. One hundred and twenty AIS patients (AIS) and twenty normal children (NC) were included in the study. Of these participants, four AIS patients and four children were used for microarray analysis. No significant difference was found between two groups in age, menarche, and Risser sign. Detailed information of the four pairs of participants is summarized in [Table 1](#tab1){ref-type="table"}. The diagnosis of AIS was made only when other causes of scoliosis, including vertebral malformation, neuromuscular disorder, and syndromic disorders, were ruled out. Participants were screened with Adams\' forward bend test. Cobb angle measured with a scoliometer was at least 10° \[[@B21]\]. Peripheral blood from each subject was added 3 times volume of Trizol LS reagent (Amboin) and immediately stored at −80°C until use.

2.2. RNA Extraction {#sec2.2}
-------------------

Total RNA was extracted using Trizol LS reagent according to the instructions recommended by the manufacturer. The RNA purity and concentration were evaluated with NanoDrop ND-1000 spectrophotometer. RNA integrity was determined with 1% formaldehyde denaturing gel electrophoresis, which revealed a good quality (data not shown).

2.3. RNA Labeling and Hybridization {#sec2.3}
-----------------------------------

Double-stranded cDNAs (containing T7 RNA polymerase promoter sequence) were synthesized from 1 mg total RNA according to the manufacturer\'s instructions (Capitalbio) and labeled with a fluorescent dye (Cy3-dCTP). Labeled cDNA was denatured at 95°C for 3 min in hybridization solution. Agilent human lncRNA + mRNA Array V3.0 was hybridized in an Agilent Hybridization Oven overnight at 42°C and washed with two consecutive solutions (0.2% SDS, 2x SSC for 5 min at 42°C, and 0.2x SSC for 5 min at room temperature).

2.4. Microarray Analysis {#sec2.4}
------------------------

The data from lncRNA + mRNA Array were used to analyze data summarization, normalization, and quality control using the GeneSpring software V11.5 (Agilent). The differentially expressed genes were selected if the change of threshold values was ≥2 or ≤−2 folds and if Benjamini-Hochberg corrected *P* values were \<0.05. The data was normalized and hierarchically clustered with CLUSTER 3.0 software. The data were performed to be Tree Visualization with Java Treeview software (Stanford University School of Medicine, Stanford, CA, USA).

2.5. Construction of the Coding-Non-Coding Gene Coexpression (CNC) Network {#sec2.5}
--------------------------------------------------------------------------

The CNC network was constructed based on the correlation analysis between the differentially expressed lncRNAs and mRNAs. LncRNAs and mRNAs with Pearson correlation coefficients not less than 0.99 were selected to draw the network using open source bioinformatics software Cytoscape (Institute of Systems Biology in Seattle). In network analysis, red nodes represent the upregulated lncRNAs, dark blue nodes represent the downregulated lncRNAs, pink nodes represent the upregulated mRNAs and light blue nodes represent the downregulated mRNAs, circular nodes represent mRNAs, triangular nodes represent lncRNAs, dashed lines represent a positive correlation, and solid lines represent an inverse correlation.

2.6. qPCR {#sec2.6}
---------

qPCR was performed using SYBR Premix Ex Taq on Thermal Cycler Dice TP800 instrument. Four lncRNAs (ENST00000440778.1, ENST00000602322.1, ENST00000414894.1, and TCONS_00028768), which revealed differentially expression, were evaluated in all participants. Total RNA (2 *μ*g) was reversely transcribed into cDNA using a PrimeScript RT reagent kit containing a gDNA Eraser (TaKaRa) according to the manufacturer\'s instructions. PCR was performed in 20 *μ*L of reaction system, including 10 *μ*L SYBR Premix Ex Taq (2x), 0.4 *μ*L of PCR forward primer (10 *μ*M), 0.4 *μ*L of PCR reverse primer (10 *μ*M), 1 *μ*L of cDNA, and 8.2 *μ*L of double-distilled water. Primers for lncRNAs and mRNA are listed in [Table 2](#tab2){ref-type="table"}. All experiments were performed in triplicates. All samples were normalized to GAPDH. The median in each triplicate was used to calculate relative lncRNAs concentrations (ΔCt = Ct median lncRNAs-Ct median GAPDH). Folds change was calculated using 2^−ΔΔCt^ methods. The differences of lncRNAs expression between patients and control were analyzed using Student\'s *t*-test within SPSS (version 16.0 SPSS Inc.). A value of *P* \< 0.05 was considered as statistically significant.

3. Results {#sec3}
==========

3.1. LncRNAs Profiles {#sec3.1}
---------------------

Tens of thousands lncRNAs were examined in microarray. A total of 139 lncRNAs revealed significantly different expression in AIS group, compared to NC group (≥2-fold) (Table S1, see Supplementary Material available online at <http://dx.doi.org/10.1155/2015/276049>). Compared to NC group, a total of 118 lncRNAs were consistently upregulated or downregulated in all tested AIS samples. ENST00000440778.1 was the most significantly downregulated lncRNA (fold change = 9.780566), while NR_024075 (Log2 fold change = 3.8194413) was the most significantly upregulated one. The heat maps of the expression ratios of lncRNAs are shown in [Figure 1(a)](#fig1){ref-type="fig"}.

3.2. mRNAs Profiles {#sec3.2}
-------------------

The expression of coding transcripts (i.e., mRNAs) was examined with microarray containing 33,982 coding transcripts probes. Up to 546 mRNAs showed significant difference between AIS and NC groups (Table S2). A total of 512 mRNAs were upregulated in AIS, while 34 mRNAs were downregulated. The heat map of the expression ratios of mRNAs is shown in [Figure 1(b)](#fig1){ref-type="fig"}. GO analysis showed that these mRNAs might be involved in bone mineralization, neuromuscular junction, skeletal system morphogenesis, and nucleotide and nucleic acid metabolism. Pathway analysis indicates that the dysregulated mRNAs are involved in cell adhesion molecules, Wnt signaling pathway, Toll-like receptor signaling pathway, MAPK signaling pathway, and so on. Coding RNAs related to major biological processes are listed in [Table 3](#tab3){ref-type="table"}. These results support the viewpoint that AIS may be a genetic disease involving musculoskeletal system.

3.3. CNC Network {#sec3.3}
----------------

In the CNC network, there were 76 lncRNAs and 370 mRNAs. A total of 446 network nodes were gained and this was associated with 1121 pairs of coexpression of lncRNAs and mRNAs. The CNC network indicates that one mRNA is correlated with one to tens of lncRNAs and*vice versa*. The whole CNC network might implicate an interregulation between lncRNAs and coding RNAs in AIS. In particular, lncRNA ENST00000602322.1 was correlated with lncRNA ENST00000422231.2 and nine coding RNAs ([Figure 2](#fig2){ref-type="fig"}).

More and more evidences indicate that lncRNAs play important roles in gene expression. Thus, we explored the correlation between lncRNAs and mRNA. More than 1000 pairs of lncRNAs and mRNAs reached an absolute correlation coefficient greater than 0.99 and a False Discovery Rate less than 0.01. Target prediction indicated that seven lncRNAs (uc002ddj.1, uc021tnw, uc021zdc.1, HIT000067310, ENST00000577528.1, ENST00000602322.1, and TCONS_00001429) may influence the expression of related mRNAs. ENST00000602322.1 and HIT000067310 may regulate the mRNA expression of PCF11 and RCAN3, respectively. The two mRNAs are expressed in muscle system and encode proteins which regulate mRNA splicing and metabolism. These lncRNAs and mRNAs may play a role in the pathogenesis of AIS. Detailed information of lncRNAs and predicted mRNAs is listed in [Table 4](#tab4){ref-type="table"}.

3.4. LncRNA Classification and Subgroup Analysis {#sec3.4}
------------------------------------------------

Recently, some special classes or 14 clusters of lncRNAs have been identified with specific function in human cells. Numerous lncRNAs were found to be transcribed from the human homeobox transcription factors (HOX) clusters \[[@B22]\]. These lncRNAs are expressed in temporal and site-specific fashions and may be associated with distinct and diverse biological processes \[[@B23], [@B24]\], such as cell proliferation, RNA binding complexes, and muscle development. In the present study, our microarray probes targeted 407 discrete transcribed regions of four human HOX loci. None of them was differentially expressed between AIS and NC.

Harrow and his colleagues defined a set of lncRNAs with enhancer-like function in human cell lines \[[@B25]\]. Depletion of these lncRNAs led to decreased expression of their neighboring protein-coding genes. In the present study, 1896 lncRNAs with enhancer-like function were detected while 4 of them were differentially expressed in AIS. The differentially expressed enhancer-like lncRNAs and their nearby coding genes (distance, 300 kb) are shown in Table S3.

3.5. qPCR Validation {#sec3.5}
--------------------

Data from microarray were validated by qPCR in twenty pairs of samples. qPCR results revealed that ENST00000602322.1, ENST00000414894.1, and TCONS_00028768 were upregulated and ENST00000440778.1 was downregulated in AIS samples (*P* \< 0.01), as compared to the control, which was consistent with those from microarray analysis ([Figure 3](#fig3){ref-type="fig"}).

3.6. Clinical Features of Validated lncRNAs {#sec3.6}
-------------------------------------------

The correlation of lncRNA expression with clinical features was further analyzed. All 120 AIS patients were grouped according to age, height, menarche, classification, severity of scoliosis (measured by Cobb angle), and Risser grade ([Table 5](#tab5){ref-type="table"}). No significant difference of lncRNAs expression was observed when patients were grouped according to menarche. The expression of ENST00000440778.1 and TCONS_00028768 was significantly different when grouped according to height (*P* \< 0.05). The expression of ENST00000602322.1 was higher in younger patients (*P* \< 0.01). Significant difference was also observed in ENST00000602322.1 expression between patients with single curve and double curves (*P* \< 0.05). Lower expression of ENST00000414894.1 was observed in patients with Cobb angle greater than 40° (*P* \< 0.05). The expression of ENST00000440778.1 was higher in patients with Risser grade ≤3 (*P* \< 0.05).

4. Discussion {#sec4}
=============

Although many clinical, epidemiological, and basic science researches were performed, the etiopathogenesis of AIS is still unclear \[[@B26]\]. Over the past decades, significant achievements have been made in profiling the molecular signatures in diseases using gene expression microarray \[[@B27]\]. Microarray has been recognized as a feasible and useful approach to explore pathogenesis and genetics of diseases and seek specific biomarkers \[[@B28]\]. Recently, hundreds of lncRNAs have been discovered, and altered lncRNAs expression has been considered to be correlated with cancer pathogenesis and muscles differentiation \[[@B29], [@B30]\]. However, the potential role of lncRNA expression in etiology and pathogenesis of AIS has not been systematically investigated.

To uncover the expression pattern of lncRNAs in AIS, we investigated the lncRNA expression signatures using microarray and found hundreds of differentially expressed lncRNAs in AIS patients. These lncRNAs may be involved in the development and progression of AIS. Based on the previous work and computer analysis, four lncRNAs (ENST00000440778.1, ENST00000602322.1, ENST00000414894.1, and TCONS_00028768) were selected to validate the consistency using qPCR. The expression of ENST00000440778.1 was downregulated in microarray and qPCR. But the expression gap between AIS and normal control was narrower in qPCR than in microarray. The difference may result from selection bias. Samples used in microarray analysis may lack representativeness, and ENST00000440778.1 expression in microarray analysis was not completely coincident between participants. Besides, it is necessary to investigate the specific lncRNAs in bigger size of samples.

In the present study, the differentially expressed mRNAs in AIS patients involve musculoskeletal development processes, including bone mineralization, neuromuscular junction, skeletal system morphogenesis, and nucleotide and nucleic acid metabolism. Pathway analysis indicates that the dysregulated mRNAs are related to cell adhesion molecules, Wnt signaling pathway, Toll-like receptor signaling pathway, MAPK signaling pathway, and so on. Precious studies have revealed the relationship between synapse formation, bone mineralization, and Wnt signaling pathway \[[@B31]--[@B33]\]. MAPK signaling pathway was also reported to be related to osteoblast differentiation and intervertebral disc cells degeneration \[[@B34], [@B35]\]. These biological processes and signaling pathway may play a significant role in the musculoskeletal system and pathogenesis of AIS.

More and more evidences reveal that lncRNAs act in both*cis* and*trans* \[[@B36], [@B37]\]. LncRNA ENST00000602322.1 locates on chromosome 11q and is adjacent to Pcf11 (Protein 1/Cleavage Factor 1). Pcf11 participates in transcription by coupling pre-mRNA \[[@B38]\]. Pcf11 is also found to play a role in transcription initiation, elongation, and mRNA export from nucleus to cytoplasm \[[@B39]--[@B41]\]. Given the key role of Pcf11 in transcription, it may not be surprising that ENST00000602322.1 may relate to the pathogenesis of AIS. The more detailed mechanisms of ENST00000602322.1 in transcription and translation need further investigation.

ENST00000440778.1 was upregulated 9.78-fold in AIS. Its expression was even higher in each AIS patient than that in healthy participants. Little is known about the function of ENST00000440778.1. However, its potential role in AIS pathogenesis was implied not only by its expression change but also by the clinical data from different height and Risser sign.

Our findings demonstrate differential lncRNA expression patterns in AIS when grouped according to different clinical features. This suggests potential significance in treatment and prognosis evaluation. Clinically, classification and curvature angle are important in evaluating surgical treatment and making operation plan in AIS \[[@B42], [@B43]\]. Onset time and Risser grade also play important roles in evaluating the progression of scoliosis \[[@B44]\]. It has been reported that lncRNAs are more specific than protein-coding mRNAs \[[@B45]\] and are easier to be detected in the blood samples of neoplastic and nonneoplastic patients using conventional PCR method \[[@B17], [@B18]\]. The differential expression of lncRNAs is potentially valuable in development of specific PCR markers and in providing more support on treatment and prognosis.

Several limitations exist in this study. First, although the different expression patterns of identified lncRNA genes suggest potential function in AIS pathogenesis, direct supporting evidence is lacking. Second, only four pairs of samples were used in microarray analysis. This may lose some important information and decrease the accuracy of biomarker selection. Third, RNA expression in peripheral blood was tested in our study. Regarding the idiopathic scoliosis being a musculoskeletal disease, tissue sample from musculoskeletal system may be more ideal targets. To accurately and comprehensively elucidate the role of lncRNAs in AIS, more comprehensive studies and laboratory and clinical researches are needed.

In summary, to the best of our knowledge, this is the first study that describes the expression profiles of human lncRNAs in AIS using microarray. Altered lncRNAs may play a potential role in the pathogenesis and/or development of this musculoskeletal disease. More work will be needed to confirm whether these lncRNAs play an essential role in the pathogenesis, treatment, and prognosis of AIS.
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Tens of thousands lncRNAs and mRNAs were examined in microarray, hundreds of which were differently expressed in AIS group compared to NC group. Detailed information of differently expressed lncRNAs and mRNAs was listed Table S1 and Table S2, respectively. Table S3 contains the differentially expressed enhancer-like lncRNAs and their nearby coding genes (distance \< 300 kb).
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![Heat maps of expression ratios (log2 scale) of lncRNAs (a) and mRNAs (b) between AIS patients and normal control. "Red" denotes high relative expression and "blue" denotes low relative expression.](BMRI2015-276049.001){#fig1}

![CNC network of lncRNA ENST00000602322.1 (labeled as p2444). Circular nodes represent mRNA; triangular nodes represent lncRNA. Detailed information of lncRNAs and mRNAs is listed in supplementary tables.](BMRI2015-276049.002){#fig2}

![Comparison between microarray and qPCR results. The columns heights represent the log-transformed median fold changes (AIS/NC) in the AIS patients compared to normal control. The validation results of the four lncRNAs indicate that the microarray results match well the qPCR results.](BMRI2015-276049.003){#fig3}

###### 

Detailed information of the four pairs of participants.

  Number   Group   Sex   Height   Age (years)   Illness history (years)   Menarche   Classification   Cobb angle (°)   Risser sign
  -------- ------- ----- -------- ------------- ------------------------- ---------- ---------------- ---------------- -------------
  A1       AIS     F     155      13.7          1                         N          PUMCIIc2         50               0
  A2       AIS     F     167      15.9          2                         Y          PUMCIIc2         40               4
  A3       AIS     F     158      15.0          1                         Y          PUMCIb           44               5
  A4       AIS     F     159      14.2          3                         Y          PUMCIIc1         44               3
  N1       NC      F     163      17.9          0                         Y          ---              0                5
  N2       NC      F     163      13.2          0                         Y          ---              0                3
  N3       NC      F     158      12.3          0                         N          ---              0                0
  N4       NC      F     170      15.5          0                         Y          ---              0                4

###### 

Primers used for qPCR.

  lncRNAs             Sense primer (5′-3′)    Antisense primer (5′-3′)   Product (bp)
  ------------------- ----------------------- -------------------------- --------------
  ENST00000602322.1   accttcccacctaccagtct    ctggggaaaccaccatagctt      150
  ENST00000440778.1   acttggttgcttttccccaca   gctttgggcttggaaagatgg      107
  ENST00000414894.1   agccgccctattcagttcac    tccaagttccgagttgtggg       148
  TCONS_00028768      gcaaacctggaaatctcggc    ggccgcagacatcatcttct       142
  GAPDH               ctataaattgagcccgcagcc   gcgcccaatacgaccaaatc       154

###### 

Genes biological processes.

  Biological processes                     Gene symbol                                                                                 Gene name                                                   Entrez gene ID   Fold changes
  ---------------------------------------- ------------------------------------------------------------------------------------------- ----------------------------------------------------------- ---------------- --------------
  Nervous system development               LTA                                                                                         "Phosphoinositide-3-kinase, catalytic, delta polypeptide"   5293             2.1513674
  TP53                                     Tumor protein p53                                                                           7157                                                        2.0308032        
  MSH2                                     "mutS homolog 2, colon cancer, nonpolyposis type 1 (E. coli)"                               4436                                                        2.0266845        
  BCL2                                     BCL2-associated athanogene 3                                                                9531                                                        2.130905         
  TP53                                     Tumor protein p53                                                                           7157                                                        2.0308032        
  NCL                                      Nuclear RNA export factor 1                                                                 10482                                                       2.00108          
  PAFAH1B1                                 "Platelet-activating factor acetylhydrolase 1b, regulatory subunit 1 (45 kDa)"              5048                                                        2.1079702        
  OLIG1                                    Oligodendrocyte transcription factor 1                                                      116448                                                      2.129439         
  PKD1                                     Polycystic kidney disease 1 (autosomal dominant)                                                                                                        2.18849          
  BTG2                                     "BTG family, member 2"                                                                      7832                                                        2.7636645        
                                                                                                                                                                                                                    
  Skeletal morphogenesis and development   BCL2                                                                                        B-Cell CLL/lymphoma 2                                       596              2.252202
  IL6ST                                    "Interleukin 6 signal transducer (gp130, oncostatin M receptor)"                            3572                                                        2.2222419        
  MYC                                      v-myc myelocytomatosis viral oncogene homolog (avian)                                       4609                                                        2.768515         
  TPP1                                     Tripeptidyl peptidase I                                                                     1200                                                        2.0187664        
  AES                                      Aminoterminal enhancer of split                                                             166                                                         2.2728803        
  ALOX15                                   Arachidonate 15-lipoxygenase                                                                246                                                         2.1062436        
                                                                                                                                                                                                                    
  Muscle development and function          BCL2                                                                                        B-Cell CLL/lymphoma 2                                       596              2.252202
  FLI1                                     Friend leukemia virus integration 1                                                         2313                                                        2.2254617        
  UTRN                                     Utrophin                                                                                    7402                                                        2.1682687        
  UTS2                                     Urotensin 2                                                                                 10911                                                       2.469184         
  HIF1A                                    "Hypoxia inducible factor 1, alpha subunit (basic helix-loop-helix transcription factor)"   3091                                                        2.028285         
  TGFBR2                                   "Transforming growth factor, beta receptor II (70/80 kDa)"                                  7048                                                        2.1115046        
  TTN                                      Titin                                                                                       7273                                                        2.7300012        
  LEF1                                     Lymphoid enhancer-binding factor 1                                                          51176                                                       3.1550286        
  HIF1A                                    "Hypoxia inducible factor 1, alpha subunit (basic helix-loop-helix transcription factor)"   3091                                                        2.028285         
  FAM65B                                   "Family with sequence similarity 65, member B"                                              9750                                                        2.247876         
  UTRN                                     Utrophin                                                                                    7402                                                        2.1682687        
                                                                                                                                                                                                                    
  Notch signaling pathway                  ADAM17                                                                                      ADAM metallopeptidase domain 17                             6868             2.0420005
  NOTCH2                                   Notch 2                                                                                     4853                                                        2.1405845        
  CTBP1                                    C-Terminal binding protein 1                                                                1487                                                        2.050679         
                                                                                                                                                                                                                    
  MAPK signaling pathway                   TAB2                                                                                        TGF-beta activated kinase 1/MAP3K7 binding protein 2        23118            2.1040483
  SOS1                                     Son of sevenless homolog 1 (Drosophila)                                                     6654                                                        2.0901704        
  DUSP16                                   Dual specificity phosphatase 16                                                             80824                                                       2.1876025        
  MAP3K1                                   Mitogen-activated protein kinase kinase kinase 1                                            4214                                                        2.343032         
  RPS6KA3                                  "Ribosomal protein S6 kinase, 90 kDa, polypeptide 3"                                        6197                                                        2.0745454        
  CD14                                     CD14 molecule                                                                               929                                                         2.3363564        
  DUSP6                                    Dual specificity phosphatase 6                                                              1848                                                        2.2230558        
  ARRB1                                    "Arrestin, beta 1"                                                                          408                                                         2.004528         
  TGFBR2                                   "Transforming growth factor, beta receptor II (70/80 kDa)"                                  7048                                                        2.1115046        
  AKT3                                     "v-akt murine thymoma viral oncogene homolog 3 (protein kinase B, gamma)"                   10000                                                       2.0013347        
  MYC                                      v-myc myelocytomatosis viral oncogene homolog (avian)                                       4609                                                        2.768515         
  TP53                                     Tumor protein p53                                                                           7157                                                        2.0308032        
  NFKB1                                    Nuclear factor of kappa light polypeptide gene enhancer in B-cells 1                        4790                                                        2.0809784        
                                                                                                                                                                                                                    
  Wnt signaling pathway                    CAMK2G                                                                                      Calcium/calmodulin-dependent protein kinase II gamma        818              2.1046312
  TCF7                                     "Transcription factor 7 (T-cell specific, HMG-box)"                                         6932                                                        2.6018746        
  PPARD                                    Peroxisome proliferator-activated receptor delta                                            5467                                                        2.1376982        
  TCF3                                     "Transcription factor 7 (T-cell specific, HMG-box)"                                         6932                                                        2.8202255        
  CAMK2D                                   Calcium/calmodulin-dependent protein kinase II delta                                        817                                                         2.5258021        
  PLCB2                                    "Phospholipase C, beta 2"                                                                   5330                                                        2.2920265        
  NFATC1                                   "Nuclear factor of activated T-cells, cytoplasmic, calcineurin-dependent 1"                 4772                                                        2.0340881        
  MYC                                      v-myc myelocytomatosis viral oncogene homolog (avian)                                       4609                                                        2.768515         
  TP53                                     Tumor protein p53                                                                           7157                                                        2.0308032        
  LEF1                                     Lymphoid enhancer-binding factor 1                                                          51176                                                       3.1550286        
  CTBP1                                    C-Terminal binding protein 1                                                                1487                                                        2.050679         
  PIAS4                                    "Protein inhibitor of activated STAT, 4"                                                    51588                                                       2.0654333        
  AES                                      Aminoterminal enhancer of split                                                             166                                                         2.2728803        
  INVS                                     Inversin                                                                                    27130                                                       2.2433844        
  LRRFIP2                                  Leucine rich repeat (in FLII) interacting protein 2                                         9209                                                        2.1049194        

Gene Ontology and Pathway analysis was performed for differentially expressed mRNAs. mRNAs involving musculoskeletal development are listed in their gene groups with associated Entrez Gene ID and fold changes per gene.

###### 

Correlation between lncRNAs and mRNAs.

  Source^a^   lncRNA              mRNA            Gene symbol   Correlation   *P* value      *cis*-Regulation^b^
  ----------- ------------------- --------------- ------------- ------------- -------------- ---------------------
  p33784      uc002ddj.1          A_21_P0011418   PKD1          0.9967847     8.29*E* − 08   Sense
  p33788      uc021tnw.1          A_24_P282108    ZZEF1         0.9976724     3.15*E* − 08   Sense
  p26337      uc021zdc.1          A_23_P122615    PNISR         0.9907335     1.98*E* − 06   Sense
  p26595      HIT000067310        A_23_P391275    RCAN3         0.9967367     8.67*E* − 08   Intergenic
  p112        ENST00000577528.1   A_23_P391275    RCAN3         0.9965706     1.01*E* − 07   Intergenic
  p2444       ENST00000602322.1   A_33_P3210139   PCF11         0.9932224     7.74*E* − 07   Antisense
  p26595      HIT000067310        A_23_P35205     RCAN3         0.9900216     2.47*E* − 06   Sense
  p29552      TCONS_00001429      A_23_P35205     RCAN3         0.9956033     2.12*E* − 07   Antisense

^a^Probe name of lncRNA. ^b^sense: the lncRNAs is a coding transcript exon on the same genomic strand; antisense: the lncRNA is transcribed from the antisense strand; intergenic: there are no overlapping or bidirectional coding transcripts nearby the lncRNA within 10 kbp.

###### 

Expressions of lncRNAs in different clinical features.

  Features               ENST00000602322.1   ENST00000440778.1   ENST00000414894.1   TCONS_00028768   
  ---------------------- ------------------- ------------------- ------------------- ---------------- ----------------
  Menarche age (y)       ≤11                 7.29 ± 0.82         4.74 ± 0.88         3.04 ± 0.52      5.51 ± 1.08
  \>11                   7.75 ± 1.20         5.09 ± 1.25         2.95 ± 0.75         5.62 ± 1.44      
                                                                                                      
  Height (cm)            ≤160                7.49 ± 1.03         4.40 ± 0.71^∗^      2.98 ± 0.59      5.05 ± 0.99^∗^
  \>160                  7.73 ± 1.17         5.34 ± 1.45^∗^      2.99 ± 0.78         5.95 ± 1.63^∗^   
                                                                                                      
  Onset of AIS (y)       ≤12                 6.73 ± 0.60^∗∗^     4.92 ± 1.09         3.09 ± 1.52      5.54 ± 1.19
  \>12                   7.86 ± 1.29^∗∗^     5.01 ± 1.17         2.87 ± 1.17         5.63 ± 1.43      
                                                                                                      
  Numbers of curves^a^   1                   7.09 ± 0.74^∗^      4.95 ± 1.40         2.79 ± 0.66      5.81 ± 1.24
  2                      7.98 ± 1.19^∗^      4.98 ± 0.95         3.10 ± 0.66         5.46 ± 1.34      
                                                                                                      
  Cobb angle (°)         ≤40                 7.60 ± 1.36         5.11 ± 1.70         2.47 ± 0.63^∗^   5.59 ± 1.60
  \>40                   7.58 ± 1.95         4.90 ± 0.72         3.38 ± 0.65^∗^      5.59 ± 1.15      
                                                                                                      
  Risser sign^b^         ≤3                  7.51 ± 1.12         4.33 ± 0.81^∗^      2.93 ± 0.60      5.37 ± 0.97
  \>3                    7.65 ± 1.07         5.21 ± 1.25^∗^      3.02 ± 0.72         5.76 ± 1.51      

Relative lncRNAs levels were normalized to GAPDH (ΔCt = CtlncRNA − CtGAPDH). Results are presented as mean ± standard deviation. ^∗^ *P* \< 0.05, ^∗∗^ *P* \< 0.01. ^a^Curves were counted and classified into single, double, and triple curves according to the apex number. ^b^Risser sign refers to the amount of calcification of the human pelvis as a measure of maturity. On a scale of 5, it gives a measurement of ossification progression; the grade of 5 means that skeletal maturity is reached.

[^1]: Academic Editor: Diego Gazzolo
